Glp-1

Tagged stories

The Long View

The Expensive Shortage Ended. The Cheap One Is Still Running.

Tirzepatide came off the FDA shortage list in December 2024 and semaglutide in February 2025. Ifosfamide, a decades-old chemotherapy used in curative regimens, is three months into a shortage the FDA expects to run into autumn and European regulators into 2027. Same country, same regulator, same manufacturing base.

By Thomas Gutierrez · 7 hours ago

Health

The Trial Showed It Was Not Worse. The Label Now Says It Cuts Risk.

The FDA has approved tirzepatide to reduce major cardiovascular events in adults with type 2 diabetes. The trial behind it compared the drug not with placebo but with dulaglutide, an older GLP-1 that already had the indication — and the result was non-inferiority, with an 8 percent lower event rate.

By Thomas Gutierrez · 34 hours ago